Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 173

1.

Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient.

Landgren O, Owen RG.

Cytometry B Clin Cytom. 2016 Jan;90(1):14-20. doi: 10.1002/cyto.b.21273. Epub 2015 Dec 22. Review.

2.

Assessment of minimal residual disease in myeloma and the need for a consensus approach.

Rawstron AC, Paiva B, Stetler-Stevenson M.

Cytometry B Clin Cytom. 2016 Jan;90(1):21-5. doi: 10.1002/cyto.b.21272. Epub 2015 Sep 23.

3.

Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.

Flores-Montero J, de Tute R, Paiva B, Perez JJ, Böttcher S, Wind H, Sanoja L, Puig N, Lecrevisse Q, Vidriales MB, van Dongen JJ, Orfao A.

Cytometry B Clin Cytom. 2016 Jan;90(1):61-72. doi: 10.1002/cyto.b.21265. Epub 2015 Jul 31. Review.

4.

Measuring disease levels in myeloma using flow cytometry in combination with other laboratory techniques: Lessons from the past 20 years at the Leeds Haematological Malignancy Diagnostic Service.

Rawstron AC, de Tute RM, Haughton J, Owen RG.

Cytometry B Clin Cytom. 2016 Jan;90(1):54-60. doi: 10.1002/cyto.b.21271. Epub 2015 Dec 21. Review.

5.

Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen.

de Tute RM, Rawstron AC, Gregory WM, Child JA, Davies FE, Bell SE, Cook G, Szubert AJ, Drayson MT, Jackson GH, Morgan GJ, Owen RG.

Haematologica. 2016 Feb;101(2):e69-71. doi: 10.3324/haematol.2015.128215. Epub 2015 Oct 15. No abstract available.

6.

Regulatory perspective on minimal residual disease flow cytometry testing in multiple myeloma.

Gormley NJ, Turley DM, Dickey JS, Farrell AT, Reaman GH, Stafford E, Carrington L, Marti GE.

Cytometry B Clin Cytom. 2016 Jan;90(1):73-80. doi: 10.1002/cyto.b.21268. Epub 2015 Jul 25.

7.

The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma.

Paiva B, Chandia M, Puig N, Vidriales MB, Perez JJ, Lopez-Corral L, Ocio EM, Garcia-Sanz R, Gutierrez NC, Jimenez-Ubieto A, Lahuerta JJ, Mateos MV, San Miguel JF.

Haematologica. 2015 Feb;100(2):e53-5. doi: 10.3324/haematol.2014.115162. Epub 2014 Nov 7. No abstract available.

8.

Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.

Rawstron AC, Child JA, de Tute RM, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro-Coy N, Drayson MT, Feyler S, Ross FM, Cook G, Jackson GH, Morgan GJ, Owen RG.

J Clin Oncol. 2013 Jul 10;31(20):2540-7. doi: 10.1200/JCO.2012.46.2119. Epub 2013 Jun 3. Erratum in: J Clin Oncol. 2013 Dec 1;31(34):4383.

PMID:
23733781
9.

Introduction to multiple myeloma special issue: The flow cytometric detection of minimal residual disease.

Preffer FI, Yuan CM, Lin P, Stetler-Stevenson M, Marti GE.

Cytometry B Clin Cytom. 2016 Jan;90(1):9-10. doi: 10.1002/cyto.b.21342. No abstract available.

10.

Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition.

Stetler-Stevenson M, Paiva B, Stoolman L, Lin P, Jorgensen JL, Orfao A, Van Dongen J, Rawstron AC.

Cytometry B Clin Cytom. 2016 Jan;90(1):26-30. doi: 10.1002/cyto.b.21249. Epub 2015 Jul 6.

11.
12.

Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma.

Korthals M, Sehnke N, Kronenwett R, Schroeder T, Strapatsas T, Kobbe G, Haas R, Fenk R.

Biol Blood Marrow Transplant. 2013 Jul;19(7):1109-15. doi: 10.1016/j.bbmt.2013.04.025. Epub 2013 May 2.

13.

Flow cytometry quality requirements for monitoring of minimal disease in plasma cell myeloma.

Oldaker TA, Wallace PK, Barnett D.

Cytometry B Clin Cytom. 2016 Jan;90(1):40-6. doi: 10.1002/cyto.b.21276. Epub 2015 Sep 4.

14.

Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics.

Chakraborty R, Muchtar E, Kumar SK, Jevremovic D, Buadi FK, Dingli D, Dispenzieri A, Hayman SR, Hogan WJ, Kapoor P, Lacy MQ, Leung N, Gertz MA.

Biol Blood Marrow Transplant. 2017 Apr;23(4):598-605. doi: 10.1016/j.bbmt.2017.01.076. Epub 2017 Jan 20.

15.

Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis.

Landgren O, Devlin S, Boulad M, Mailankody S.

Bone Marrow Transplant. 2016 Dec;51(12):1565-1568. doi: 10.1038/bmt.2016.222. Epub 2016 Sep 5.

16.

Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.

Gay F, Oliva S, Petrucci MT, Conticello C, Catalano L, Corradini P, Siniscalchi A, Magarotto V, Pour L, Carella A, Malfitano A, Petrò D, Evangelista A, Spada S, Pescosta N, Omedè P, Campbell P, Liberati AM, Offidani M, Ria R, Pulini S, Patriarca F, Hajek R, Spencer A, Boccadoro M, Palumbo A.

Lancet Oncol. 2015 Dec;16(16):1617-29. doi: 10.1016/S1470-2045(15)00389-7. Epub 2015 Nov 17.

17.

The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma.

Davies FE, Forsyth PD, Rawstron AC, Owen RG, Pratt G, Evans PA, Richards SJ, Drayson M, Smith GM, Selby PJ, Child JA, Morgan GJ.

Br J Haematol. 2001 Mar;112(3):814-9.

PMID:
11260088
18.

Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.

Paiva B, Vidriales MB, Cerveró J, Mateo G, Pérez JJ, Montalbán MA, Sureda A, Montejano L, Gutiérrez NC, García de Coca A, de Las Heras N, Mateos MV, López-Berges MC, García-Boyero R, Galende J, Hernández J, Palomera L, Carrera D, Martínez R, de la Rubia J, Martín A, Bladé J, Lahuerta JJ, Orfao A, San Miguel JF; GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Groups.

Blood. 2008 Nov 15;112(10):4017-23. doi: 10.1182/blood-2008-05-159624. Epub 2008 Jul 31.

19.

Bortezomib and melphalan conditioning increases the rate of complete response and MRD negativity for patients with multiple myeloma undergoing single autologous stem cell transplant.

Jimenez-Zepeda VH, Duggan P, Neri P, Chaudhry A, Murray K, Culham M, Luider J, Fourie T, Rashid-Kolvear F, Bahlis NJ.

Leuk Lymphoma. 2016;57(4):973-6. doi: 10.3109/10428194.2015.1085534. Epub 2015 Oct 8. No abstract available.

PMID:
26450458
20.

MRD Testing in Multiple Myeloma: The Main Future Driver for Modern Tailored Treatment.

Landgren O, Lu SX, Hultcrantz M.

Semin Hematol. 2018 Jan;55(1):44-50. doi: 10.1053/j.seminhematol.2018.03.001. Epub 2018 Mar 5. Review.

PMID:
29759154

Supplemental Content

Support Center